| Immunodesign of experimental sepsis by cecal ligation and puncture D Rittirsch, MS Huber-Lang, MA Flierl, PA Ward Nature protocols 4 (1), 31-36, 2009 | 2126 | 2009 |
| Generation of C5a in the absence of C3: a new complement activation pathway M Huber-Lang, JV Sarma, FS Zetoune, D Rittirsch, TA Neff, SR McGuire, ... Nature medicine 12 (6), 682-687, 2006 | 1186 | 2006 |
| Molecular intercommunication between the complement and coagulation systems U Amara, MA Flierl, D Rittirsch, A Klos, H Chen, B Acker, UB Brückner, ... The Journal of Immunology 185 (9), 5628-5636, 2010 | 798 | 2010 |
| Interaction between the coagulation and complement system U Amara, D Rittirsch, M Flierl, U Bruckner, A Klos, F Gebhard, JD Lambris, ... Current topics in complement II, 68-76, 2008 | 601 | 2008 |
| Complement as a target in COVID-19? AM Risitano, DC Mastellos, M Huber-Lang, D Yancopoulou, C Garlanda, ... Nature Reviews Immunology 20 (6), 343-344, 2020 | 545 | 2020 |
| Innate immune responses to trauma M Huber-Lang, JD Lambris, PA Ward Nature immunology 19 (4), 327-341, 2018 | 530 | 2018 |
| Phagocyte-derived catecholamines enhance acute inflammatory injury MA Flierl, D Rittirsch, BA Nadeau, AJ Chen, JV Sarma, FS Zetoune, ... Nature 449 (7163), 721-725, 2007 | 521 | 2007 |
| Protective effects of C5a blockade in sepsis BJ Czermak, V Sarma, CL Pierson, RL Warner, M Huber-Lang, NM Bless, ... Nature medicine 5 (7), 788-792, 1999 | 510 | 1999 |
| Functional roles for C5a receptors in sepsis D Rittirsch, MA Flierl, BA Nadeau, DE Day, M Huber-Lang, CR Mackay, ... Nature medicine 14 (5), 551-557, 2008 | 484 | 2008 |
| New insights of an old defense system: structure, function, and clinical relevance of the complement system C Ehrnthaller, A Ignatius, F Gebhard, M Huber-Lang Molecular medicine 17, 317-329, 2011 | 318 | 2011 |
| Role of C5a in multiorgan failure during sepsis M Huber-Lang, VJ Sarma, KT Lu, SR McGuire, VA Padgaonkar, RF Guo, ... The Journal of Immunology 166 (2), 1193-1199, 2001 | 298 | 2001 |
| The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 S Mastaglio, A Ruggeri, AM Risitano, P Angelillo, D Yancopoulou, ... Clinical immunology 215, 108450, 2020 | 296 | 2020 |
| Complement-induced impairment of innate immunity during sepsis MS Huber-Lang, EM Younkin, JV Sarma, SR McGuire, KT Lu, RF Guo, ... The Journal of Immunology 169 (6), 3223-3231, 2002 | 286 | 2002 |
| Bone formation in a long bone defect model using a platelet-rich plasma-loaded collagen scaffold MR Sarkar, P Augat, SJ Shefelbine, S Schorlemmer, M Huber-Lang, ... Biomaterials 27 (9), 1817-1823, 2006 | 269 | 2006 |
| Minimum quality threshold in pre-clinical sepsis studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis MF Osuchowski, A Ayala, S Bahrami, M Bauer, M Boros, JM Cavaillon, ... Intensive care medicine experimental 6, 1-6, 2018 | 267 | 2018 |
| Generation of C5a by phagocytic cells M Huber-Lang, EM Younkin, JV Sarma, N Riedemann, SR McGuire, ... The American journal of pathology 161 (5), 1849-1859, 2002 | 263 | 2002 |
| Polytrauma—pathophysiology and management principles F Gebhard, M Huber-Lang Langenbeck's archives of surgery 393, 825-831, 2008 | 260 | 2008 |
| Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside intervention DC Mastellos, D Yancopoulou, P Kokkinos, M Huber‐Lang, ... European journal of clinical investigation 45 (4), 423-440, 2015 | 233 | 2015 |
| Adverse functions of IL‐17A in experimental sepsis MA Flierl, D Rittirsch, H Gao, LM Hoesel, BA Nadeau, DE Day, ... Wiley Periodicals, Inc., 2008 | 233 | 2008 |
| Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy DC Mastellos, BGPP da Silva, BAL Fonseca, NP Fonseca, ... Clinical Immunology 220, 108598, 2020 | 231 | 2020 |
